Dr. Reddy's Laboratories Limited (BVMF:R1DY34)

Market Cap	61.46B
Revenue (ttm)	20.53B
Net Income (ttm)	3.52B
Shares Out	n/a
EPS (ttm)	4.22
PE Ratio	17.47
Forward PE	20.83
Dividend	0.06 (0.53%)
Ex-Dividend Date	Jul 9, 2025

Volume	10
Average Volume	261
Open	11.96
Previous Close	12.60
Day's Range	11.96 - 11.96
52-Week Range	11.96 - 16.30
Beta	0.36
RSI	32.96
Earnings Date	Jan 26, 2026

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1984
• Employees: 27,811
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: R1DY34

Financial Performance

In 2024, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.

Financial numbers in INR